TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30089179

Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix IOL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FineVision Micro F IOL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TECNIS Symfony IOL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All three IOLs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trifocal IOLs vs EDOF IOL
Number of subjects: 60
Study: 27658183

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) with antioxidants
Number of subjects: 61

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF)
Number of subjects: 61
Study: 24880643

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) at 0.2 mg/kg bodyweight
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) at 0.4 mg/kg bodyweight
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Both IVM and MOX
Number of subjects: 320
Study: 23731996

Group type: EXPERIMENTAL
Intervention: Comprehensive chromosome screening (CCS)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 155
Study: 20153597

Group type: EXPERIMENTAL
Intervention: Pictorial pamphlet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prose pamphlet
Number of subjects: 100
Study: 18400671

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Easwaran's Eight-Point Program (EPP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 44
Study: 16358301

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at a dose of 1,000 mg/m2 given as a 36-hour continuous infusion
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 13
Study: 11782656

Group type: EXPERIMENTAL
Intervention: Fatigue condition (muscular fatigue induced in tibialis anterior by isometric test at 70% of maximal voluntary contraction for 40 seconds)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal condition (no fatigue)
Number of subjects: 8
Study: 9521199

Group type: COMPARATOR
Intervention: Double therapy (CsA [10 mg/kg/day] plus prednisone)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Triple therapy (CsA [6 mg/kg/day] plus azathioprine plus prednisone)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 250
Study: 8004841

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bisoprolol (all doses combined)
Number of subjects: 240
Study: 2590974

Group type: EXPERIMENTAL
Intervention: Schlegel's panfundoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three mirror lens
Number of subjects: 0
Study: 788293

Group type: EXPERIMENTAL
Intervention: Flutamide (high or low dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diethylstilbestrol (1 mg daily)
Number of subjects: 15
Study: 29444502

Group type: EXPERIMENTAL
Intervention: Combination of 1% starch and 10% sucrose
Number of subjects: 18

Group type: COMPARATOR
Intervention: 10% sucrose
Number of subjects: 18
Study: 27533335

Group type: EXPERIMENTAL
Intervention: Sucrose, swaddling, and vibration (using a handheld battery-powered vibrator, Hz = 92)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sucrose and swaddling
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sucrose, swaddling, and vibration
Number of subjects: 56
Study: 23893098

Group type: EXPERIMENTAL
Intervention: Project SEARCH plus ASD Supports (treatment group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study: 22399630

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC5) on day 1 with escalating oral topotecan (3.0 mg/m² starting dose) on days 1, 8, and 15, every 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC5) with oral topotecan
Number of subjects: 18
Study: 20592644

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for adjusting doses of HIV-1 protease inhibitors (PIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 18179469

Group type: EXPERIMENTAL
Intervention: Urban children
Number of subjects: 534

Group type: COMPARATOR
Intervention: Rural children
Number of subjects: 534

Group type: COMPARATOR
Intervention: Rural/urban dwelling
Number of subjects: 534
Study: 15913800

Group type: EXPERIMENTAL
Intervention: 4-week ribavirin (RIB) administration followed by 24-week combination treatment with interferon (IFN) and RIB (Group A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 24-week combination treatment with interferon (IFN) and ribavirin (RIB) only (Group B)
Number of subjects: 81
Study: 12806908

Group type: EXPERIMENTAL
Intervention: Logotherapy (added to loxoprofen sodium treatment)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Loxoprofen sodium (NSAID) only
Number of subjects: 21
Study: 9926970

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg i.v. every 3 weeks for a maximum of six cycles
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg i.v. every 3 weeks for a maximum of six cycles
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 70
Study: 7489963

Group type: EXPERIMENTAL
Intervention: dDAVP, 0.5 microgram/kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study: 2178523

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylephrine (premedication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study: 111876

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate (Opticrom)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29795123

Group type: EXPERIMENTAL
Intervention: Implementation-planning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard-of-care diet advice
Number of subjects: 60
Study: 26853244

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy, noise cancelling earplugs, and eye mask
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 25234603

Group type: EXPERIMENTAL
Intervention: ECI‐guided ablation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (non‐ECI‐guided ablation)
Number of subjects: 101
Study: 22790795

Group type: EXPERIMENTAL
Intervention: Tai chi intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 39
Study: 21465722

Group type: EXPERIMENTAL
Intervention: Enhanced family planning outreach program
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard services (control)
Number of subjects: 11
Study: 17372126

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg daily) and vitamin D2 (1,000 IU)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo and vitamin D2 (1,000 IU)
Number of subjects: 121
Study: 16129914

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (Methylprednisolone, Pentoxifylline, Saline)
Number of subjects: 45
Study: 12114036

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study: 10566368

Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 0

Group type: COMPARATOR
Intervention: Touchscreen assessments
Number of subjects: 0
Study: 8607737

Group type: EXPERIMENTAL
Intervention: Perceptual Speed test
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Time Estimation task
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tracking-Reaction dual task
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: WAIS Symbol-Digit Substitution subtest
Number of subjects: 38
Study: 1783036

Group type: EXPERIMENTAL
Intervention: Target selection of a long vertical bar with short vertical bars on either side having opposite disparities.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Fixation of the long vertical bar while stabilizing the configuration.
Number of subjects: 2
Study: 6168848

Group type: EXPERIMENTAL
Intervention: Disopyramide (600 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mexiletine (600-1000 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Disopyramide plus Mexiletine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study: 30511293

Group type: EXPERIMENTAL
Intervention: Total glucosides of peony (TGP)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 28483330

Group type: EXPERIMENTAL
Intervention: Posterior RARP
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anterior RARP
Number of subjects: 120
Study: 25388643

Group type: EXPERIMENTAL
Intervention: Intra-articular injection hyaluronic acid (IAHA) for 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oral glucosamine sulfate (GS) for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intra-articular injection hyaluronic acid (IAHA)
Number of subjects: 150
Study: 25064093

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme (motor training and cognitive-behavioural therapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual-care alone (control group)
Number of subjects: 20
Study: 22760571

Group type: EXPERIMENTAL
Intervention: Motion-controlled video games (MC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Television watching
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional video games (VG)
Number of subjects: 120
Study: 19641052

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 218

Group type: COMPARATOR
Intervention: La Premiere LM
Number of subjects: 218
Study: 17662095

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% and lidocaine 2% mixture (group 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.75% (group 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% (group 3)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All agents (group 1, group 2, group 3)
Number of subjects: 105
Study: 15787921

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.2% (1 ml x kg(‐1))
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% (1 ml x kg(‐1))
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.2% (1 ml x kg(‐1))
Number of subjects: 182

Group type: COMPARATOR
Intervention: ropivacaine and levobupivacaine
Number of subjects: 182
Study: 11923128

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with sequential paclitaxel and doxorubicin-based combination chemotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pathology from mastectomy specimens
Number of subjects: 100
Study: 9706795

Group type: EXPERIMENTAL
Intervention: RHL (rose-hip drink with fermented oats containing Lactobacillus plantarum DSM 9843)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RHL
Number of subjects: 48

Group type: COMPARATOR
Intervention: RH (pure rose-hip drink)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48

Group type: COMPARATOR
Intervention: RH
Number of subjects: 48
Study: 7678047

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 43
Study: 3524419

Group type: COMPARATOR
Intervention: Tobramycin and ticarcillin for 27 to 62 days (mean, 42 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ceftazidime 4 g per day for 26 to 63 days (mean, 45 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 18
Study: 29560635

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Neural Mobilization (NM)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with Neural Mobilization (EA+NM)
Number of subjects: 62
Study: 26902950

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month formulation (PP3M)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month formulation (PP1M)
Number of subjects: 1016
Study: 24521106

Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy
Number of subjects: 2001

Group type: COMPARATOR
Intervention: Nodal observation
Number of subjects: 2001
Study: 22381051

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 48

Group type: COMPARATOR
Intervention: Propofol-remifentanil anesthesia
Number of subjects: 48
Study: 20116803

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced cardiac magnetic resonance (ceCMR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Electrocardiographic QRS scoring
Number of subjects: 34
Study: 18052520

Group type: EXPERIMENTAL
Intervention: learner‐centered hand washing program
Number of subjects: 0
Study: 16229991

Group type: EXPERIMENTAL
Intervention: Sequential intravenous/oral moxifloxacin (400 mg once a day)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Intravenous piperacillin-tazobactam (3.0/0.375 g every 6 h) followed by oral amoxicillin-clavulanate (800 mg every 12 h)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Sequential intravenous/oral moxifloxacin
Number of subjects: 367

Group type: COMPARATOR
Intervention: Intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate
Number of subjects: 367
Study: 12095814

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optical pachymetry (OP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (contralateral eye without contact lens)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OP
Number of subjects: 20
Study: 10447907

Group type: EXPERIMENTAL
Intervention: 22-gauge Quincke needle
Number of subjects: 57

Group type: COMPARATOR
Intervention: 22-gauge Whitacre needle
Number of subjects: 57
Study: 8522666

Group type: EXPERIMENTAL
Intervention: Urinastatin (100,000 U dose immediately after arrival, followed by three 100,000 U doses at 8-hour intervals within the first 24 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation (CPR) procedures
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urinastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (standard CPR)
Number of subjects: 40
Study: 2034708

Group type: EXPERIMENTAL
Intervention: Electrical stimulation in conjunction with voluntary isometric exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biofeedback in conjunction with voluntary isometric exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 30
Study: 6794083

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 21
Study: 31866328

Group type: EXPERIMENTAL
Intervention: Amikacin Inhale (400 mg, aerosolised, administered every 12 h for 10 days)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo (saline, aerosolised, administered every 12 h for 10 days)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Amikacin Inhale
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study: 29671202

Group type: EXPERIMENTAL
Intervention: Somapacitan (0.01-0.32 mg/kg in healthy adults; 0.02-0.12 mg/kg in adults with GHD; 0.02-0.16 mg/kg in children with GHD)
Number of subjects: 0
Study: 27694343

Group type: EXPERIMENTAL
Intervention: Brain amyloid load (measured by florbetapir F18 positron emission tomography)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 5-repetition chair rise performance (maximum speed)
Number of subjects: 269
Study: 26359749

Group type: EXPERIMENTAL
Intervention: Parent-mediated intervention (iBASIS-VIPP)
Number of subjects: 54
Study: 22706336

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily (1 drop PM)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily (1 drop AM and PM)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Comparison of Latanoprost vs Timolol
Number of subjects: 142
Study: 21193924

Group type: EXPERIMENTAL
Intervention: Decoupled crank system
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional crank system
Number of subjects: 18
Study: 19550390

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (including dietary restriction programme)
Number of subjects: 24
Study: 17760930

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 210
Study: 15476485

Group type: EXPERIMENTAL
Intervention: Tacrolimus and Mycophenolate Mofetil (MMF) with a 7-day course of prednisolone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Anti-CD25 monoclonal antibody (anti-CD25 mAb) administered to high immunological risk patients
Number of subjects: 101
Study: 11544563

Group type: EXPERIMENTAL
Intervention: Diabetic pregnancies
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Type I diabetes pregnancies
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus pregnancies
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Diabetic pregnancies complicated by gestational hypertension
Number of subjects: 76

Group type: COMPARATOR
Intervention: Uncomplicated pregnancies
Number of subjects: 76
Study: 9766411

Group type: EXPERIMENTAL
Intervention: Nebulized furosemide 1 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nebulized furosemide 2 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no nebulization)
Number of subjects: 13
Study: 8877293

Group type: EXPERIMENTAL
Intervention: Glibenclamide (0.33 or 3.3 micrograms.min‐1.dl‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Glimepiride (2.5 micrograms.min‐1.dl‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 36
Study: 2565995

Group type: EXPERIMENTAL
Intervention: 4 micrograms SOM 1397 CL
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 12 micrograms SOM 1397 CL
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 24 micrograms SOM 1397 CL
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 microgram SOM 1397 CL
Number of subjects: 10
Study: 337094

Group type: EXPERIMENTAL
Intervention: Carbenicillin, cephalothin, and gentamicin (CCG)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Continue antibiotics (CCG + chloramphenicol or clindamycin)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Stop antibiotics
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CCG
Number of subjects: 51
Study: 31836199

Group type: EXPERIMENTAL
Intervention: D-VMP (daratumumab, bortezomib, melphalan, and prednisone)
Number of subjects: 706

Group type: COMPARATOR
Intervention: VMP (bortezomib, melphalan, and prednisone)
Number of subjects: 706
Study: 30300017

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV_G)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (C_G)
Number of subjects: 42
Study: 26324740

Group type: EXPERIMENTAL
Intervention: lenvatinib 24 mg orally per day (n = 261)
Number of subjects: 392

Group type: COMPARATOR
Intervention: placebo (n = 131)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: lenvatinib 24 mg orally per day
Number of subjects: 392
Study: 23921307

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Metoprolol (100 mg/d)
Number of subjects: 72
Study: 21860340

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP) sublingual tablet (14-20 mg)
Number of subjects: 3
Study: 19626663

Group type: COMPARATOR
Intervention: INGAP peptide 600 mg/day
Number of subjects: 189

Group type: COMPARATOR
Intervention: INGAP peptide 300 mg/day
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 17377106

Group type: EXPERIMENTAL
Intervention: Ketamine (intraoperative 0.3 mg/kg and postoperative infusion at 0.1 mg x kg(‐1) x h(‐1))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (equivalent volume/rate of normal saline)
Number of subjects: 120
Study: 15848980

Group type: EXPERIMENTAL
Intervention: Braun Plaque Control 3D (Electric toothbrush)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SuperBrush (Manual triple-headed brush)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CrossAction (Manual toothbrush)
Number of subjects: 30
Study: 11371693

Group type: EXPERIMENTAL
Intervention: VOICES/VOCES intervention
Number of subjects: 10000
Study: 10434906

Group type: EXPERIMENTAL
Intervention: PSA level over 20 ng ml‐1
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PSA level below 20 ng ml‐1 and Gleason score below 6
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Mean PSA values of men with skeletal metastases
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Mean PSA values of men with locally confined disease
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PSA values of men with lymph node metastasis
Number of subjects: 102
Study: 8140873

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 30
Study: 3555604

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 22
Study: 29332760

Group type: EXPERIMENTAL
Intervention: Ischemic compression + kinesiotherapy (G1, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Kinesiotherapy (G2, n = 10)
Number of subjects: 20
Study: 27912108

Group type: EXPERIMENTAL
Intervention: Communication support program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 110